Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort

Lea Nymand*, Mia Louise Nielsen, Ida Vittrup, Anne Sofie Halling, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

2 Citationer (Scopus)

Abstract

Background
Despite previous attempts to classify atopic dermatitis (AD) into subtypes (e.g. extrinsic vs. intrinsic), there is a need to better understand specific phenotypes in adulthood.

Objectives
To identify, using machine learning (ML), adult AD phenotypes.

Methods
We used unsupervised cluster analysis to identify AD phenotypes by analysing different responses to predetermined variables (age of disease onset, severity, itch and skin pain intensity, flare frequency, anatomical location, presence and/or severity of current comorbidities) in adults with AD from the Danish Skin Cohort.

Results
The unsupervised cluster analysis resulted in five clusters where AD severity most clearly differed. We classified them as ‘mild’, ‘mild-to-moderate’, ‘moderate’, ‘severe’ and ‘very severe’. The severity of multiple predetermined patient-reported outcomes was positively associated with AD, including an increased number of flare-ups and increased flare-up duration and disease severity. However, an increased severity of rhinitis and mental health burden was also found for the mild-to-moderate phenotype.

Conclusions
ML confirmed the use of disease severity for the categorization of phenotypes, and our cluster analysis provided novel detailed information about how flare patterns and duration are associated with AD disease severity.
OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind190
Udgave nummer2
Sider (fra-til)207-215
Antal sider9
ISSN0007-0963
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
This study was funded by AbbVie A/S, Emdrupvej 28 C, 2100 Copenhagen, Denmark ("AbbVie") . The study protocol was designed in collaboration with AbbVie. Once the study protocol was approved, AbbVie had no influence on conduct of the study, data analysis or interpretation of the results.

Publisher Copyright:
© 2024 Blackwell Publishing Ltd. All rights reserved.

Citationsformater